Correlation Between Sarepta Therapeutics and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Sarepta Therapeutics and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sarepta Therapeutics and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sarepta Therapeutics and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Sarepta Therapeutics and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sarepta Therapeutics with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sarepta Therapeutics and Acrivon Therapeutics,.

Diversification Opportunities for Sarepta Therapeutics and Acrivon Therapeutics,

0.36

Correlation Coefficient

Sarepta Therapeutics  Acrivon Therapeutics,

Weak diversification

The 3 months correlation between Sarepta and Acrivon is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Sarepta Therapeutics and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Sarepta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sarepta Therapeutics are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Sarepta Therapeutics i.e., Sarepta Therapeutics and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Sarepta Therapeutics and Acrivon Therapeutics,

Given the investment horizon of 90 days Sarepta Therapeutics is expected to generate 0.7 times more return on investment than Acrivon Therapeutics,. However, Sarepta Therapeutics is 1.42 times less risky than Acrivon Therapeutics,. It trades about 0.02 of its potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about -0.05 per unit of risk. If you would invest  12,465  in Sarepta Therapeutics on September 13, 2024 and sell it today you would earn a total of  74.00  from holding Sarepta Therapeutics or generate 0.59% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Sarepta Therapeutics  vs.  Acrivon Therapeutics, Common

Sarepta Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Sarepta Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Sarepta Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Sarepta Therapeutics and Acrivon Therapeutics,

The main advantage of trading using opposite Sarepta Therapeutics and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sarepta Therapeutics position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind Sarepta Therapeutics and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.